Article

AcuFocus corneal inlay chosen as design award finalist

AcuFocus Inc. is a finalist in the 2012 Medical Design Excellence Awards (MDEA) for its proprietary corneal inlay (Kamra).

Irvine, CA-AcuFocus Inc. is a finalist in the 2012 Medical Design Excellence Awards (MDEA) for its proprietary corneal inlay (Kamra).

The inlay is designed to reverse the effects of presbyopia and restore near and immediate vision. It is currently an investigational device in the United States.

The MDEA recognize contributions and advances in the design of medical products. Entries are evaluated based on their design and engineering features, including innovative use of materials, user-related functions that improve healthcare delivery and change traditional medical attitudes or practices, features that provide enhanced benefits to the patient, and the ability of the product development team to overcome design and engineering challenges so that the product meets its clinical objectives.

“We’re excited to be recognized by the MDEA for our ongoing accomplishments in the medical device industry,” said Ed Peterson, chief executive officer of AcuFocus. “[The proprietary inlay] is the product of boundless hard work and innovation by our entire team, which includes clinical input from surgeons around the world. In light of the ongoing acceptance of the inlay globally, with [more than] 10,000 patients today [having received the implants] and high patient satisfaction, to be [also] chosen as a finalist for this esteemed award is a great honor.”

The winners will be announced May 23. For more information on the awards, visit www.MDEAwards.com.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.